Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | GLS | O94925 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12321255 | 1.00 | HPGD (0.47) | HPGDKDM4EPKMGLSRECQL | |
| SCHEMBL1773305 | 1.00 | HPGD (0.47) | HPGDKDM4EPKMGLSRECQL | |
| SCHEMBL3220460 | 0.85 | HPGD (0.51) | HPGDKDM4EPKMGLSRECQL | |
| SCHEMBL1774284 | 0.85 | HPGD (0.44) | HPGDKDM4EPKMGLSRECQL | |
| SCHEMBL1774285 | 0.85 | HPGD (0.44) | HPGDKDM4EPKMGLSRECQL | |
| SCHEMBL30293339 | 0.85 | FAAH (0.53) | HPGDKDM4EPKMRECQLEPHX1 | |
| SCHEMBL24999158 | 0.84 | HPGD (0.48) | HPGDKDM4EPKMGLSRECQL | |
| SCHEMBL30758937 | 0.84 | GLS (0.49) | HPGDGLSNR1H2 | |
| SCHEMBL30759116 | 0.84 | GLS (0.49) | HPGDGLSNR1H2 | |
| SCHEMBL24208478 | 0.83 | HPGD (0.47) | HPGDKDM4EPKMGLSRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2492266-B1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2015-08-26 | — | — | EP | disclosed |
| US-8785462-B2 | 5-hydroxypyrimidine-4-carboxamide derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-07-22 | — | — | US | disclosed |
| US-20120220609-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-08-30 | — | — | US | disclosed |
| US-20110112103-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220609-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE DERIVATIVE | EPOR, EGLN2, EGLN1 | HPGD 320/4885KDM4E 228/4885PKM 2284/4885 |
| US-20110112103-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE COMPOUND | EPOR, CBR1, CBR3 | HPGD 734/4885KDM4E 377/4885PKM 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.